Research evidence and policy-making: increasing demand, publication speed and public scrutiny
COVID-19 has increased demand for research evidence. In response the research and publication processes have sped up. What does this mean for scrutiny?
![](https://post.parliament.uk/content/uploads/sites/3/2021/04/adrien-delforge-LLNnPXNwzDM-unsplash-568x426.jpg)
In its 2017 Industrial Strategy, the UK Government set out a target of investing 2.4% of GDP on R&D by 2027. How is it planning to reach this target? What are the uncertainties emerging from COVID-19 and the withdrawal from the European Union?
DOI: https://doi.org/10.58248/HS48
The UK is a global leader in research.1 Research and development (R&D) in the UK is mainly funded by the business sector (55% in 2018).2,3 Funding from the public sector (including government, UKRI and the devolved higher education funding councils) represented 26% of the total in 2018, while overseas investment the remaining 14%.2,3 In the 2017 Industrial Strategy, the UK Government set a target of spending 2.4% of GDP on R&D by 2027 (through both public and private investments) and committed to increase this to 3% in the longer-term.4,5 The latest government strategies set out the opportunities for UK research to reach these targets.6 However, there is current uncertainty due to the future model of Horizon Europe membership not being clear and repercussions from the COVID-19 pandemic.
A series of challenges for the R&D landscape also emerged following the UK withdrawal from the EU. After initial uncertainty about the UK’s access to EU research funding and opportunities to collaborate on multinational research projects,28,29 the UK-EU Trade and Cooperation Agreement laid the necessary groundwork for continued UK participation in some EU programmes, including most aspects of Horizon Europe, the world’s largest multilateral research funding programme.30–33 Aligned regulations and free data sharing are key aspects of international collaborations. In February 2021 the European Commission drafted its data adequacy decisions, recognising the UK’s data protection standards as adequate to allow data sharing between the UK and the EU.34–36 However, the draft still needs to be presented to the EU member states and formally approved.36,37 If not, this could have significant impact on multinational research projects. There are also some concerns around the alignment of regulations, including those concerning future international clinical trials and medicines.38,39
To attract overseas researchers to the UK, changes to the immigration system have been announced. These include the introduction of the Global Talent Visa (a new visa system to provide top scientists with fast-tracked entry into the UK with effect from February 2020), a points-based visa introduced from January 2021 and an elite points-based visa to promote high-skilled migration, to be introduced in March 2022.17,18,40,41 Concerns about visa costs, together with payment of the Immigration Health Surcharge for people planning to stay for more than 6 months, have been raised and it is not clear what impact this will have on overseas researchers’ willingness to come to or stay in the UK.41–44 Migration from the EU declined between 2016 and 2018, but has started to stabilise since 2018.45
The long-term economic impact of COVID-19 on future research allocations is unknown. In terms of EU-UK collaborations, it is unclear whether UK participation will continue in the same capacity or new policies are needed to restructure frameworks allowing international collaborations. Other unknowns include whether the cost of joining Horizon Europe will come from existing R&D budget allocations (such as UKRI funding) or from additional spending, whether the £800m pledged for ARIA will be subtracted from UKRI budget allocations, and the effects of UKRI budget reduction on international projects. The Government’s 2021/22 R&D allocations will be published in due course. 46
High impact/likelihood, impacts being felt now.
Experts have helped us identify 30 areas of change to help the UK Parliament prepare for the future.
Photo by Chris Liverani on Unsplash
COVID-19 has increased demand for research evidence. In response the research and publication processes have sped up. What does this mean for scrutiny?
COVID-19 has brought the drivers behind health inequality into sharp focus. But are there resources available to meet research and policy needs?
GDP and income inequality both influence population health. How might the COVID-19 outbreak widen economic inequalities in the long-term?